Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Neuro Endocrinol Lett ; 33 Suppl 2: 55-9, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23183511

RESUMEN

OBJECTIVES: Lipoprotein (a) [Lp(a)], together with other serum lipoproteins have an important role in the pathogenesis of coronary heart disease. The objective of the study was to assess the association between plasma levels of Lp(a) with the extent of angiographically defined coronary artery disease (CAD). PATIENTS AND METHODS: A total of 518 consecutive patients (66 % males) underwent coronary angiography in connection with lipids and lipoprotein determinations between 1st January and 31st May 2010. Most of the patients were treated with lipid lowering therapy (77 % statins). Modified angiographic Gensini Score (GS) and adjusted angiographic score (AS) were used to reflect the extent of coronary atherosclerosis. RESULTS: Both GS and AS angiographic scores correlated significantly with age, male gender, statin therapy and inversely with left ventricular ejection fraction (p<0.05-0.01 for all). The results showed significant inverse correlation of HDL cholesterol levels with GS and AS (r=-0.16, p<0.001), and apolipoprotein A levels with GS and AS (r=-0.20, p<0.0001) and a positive correlation of Lp(a) levels with angiographic score (r=0.13, p<0.01) and with adjusted angiographic score (r=0.16, p<0.01). Regression analysis showed only Lp(a) concentration was an independent lipid factor that correlated with the extent of CAD. CONCLUSION: Only Lp(a) levels correlated with the extent of coronary artery disease as assessed with coronary angiography in patients treated with lipid lowering therapy.


Asunto(s)
Enfermedad de la Arteria Coronaria/sangre , Enfermedad de la Arteria Coronaria/epidemiología , Dislipidemias/sangre , Dislipidemias/epidemiología , Hipolipemiantes/uso terapéutico , Lipoproteína(a)/sangre , Índice de Severidad de la Enfermedad , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Dislipidemias/tratamiento farmacológico , Femenino , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Factores de Riesgo
2.
CJC Open ; 3(2): 217-220, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33106785

RESUMEN

We present the case of a patient with a nonbacterial thrombotic aortic valve endocarditis experiencing severe thromboembolic complications and an acute right internal carotid artery occlusion in the context of a paraneoplastic syndrome and an asymptomatic severe acute respiratory syndrome coronavirus-2 infection, despite treatment with different and overlapping anticoagulant medications. Patients with increased thrombogenicity due to an underlying disease might be at increased risk for thrombotic events during a severe acute respiratory syndrome coronavirus-2 infection.


Nous présentons le cas d'un patient atteint d'endocardite thrombotique non bactérienne de la valve aortique et présentant des complications thromboemboliques graves et une occlusion aiguë de la carotide interne droite dans le contexte d'un syndrome paranéoplasique et d'une infection à coronavirus du syndrome respiratoire aigu sévère 2 (SRAS-CoV-2) asymptomatique, malgré différentes anticoagulothérapies se chevauchant. Les patients présentant une thrombogénicité accrue en raison d'une affection sous-jacente pourraient courir un plus grand risque d'événement thrombotique en cas d'infection à SRAS-CoV-2.

3.
Clin Cardiol ; 44(9): 1243-1248, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34312888

RESUMEN

BACKGROUND: Uninterrupted direct oral anticoagulation (DOAC) in AF-ablation is recommended, proven by randomized trials. The outcome and the periinterventional differences between DOACs and VKA in the real world clinical practice are discussed controversial. HYPOTHESIS: To investigate efficiency and safety of uninterrupted DOAC therapy compared to VKA during AF-Ablation in real world setting with a focus on periinterventional heparin dosage.


Asunto(s)
Fibrilación Atrial , Ablación por Catéter , Administración Oral , Anticoagulantes/efectos adversos , Fibrilación Atrial/complicaciones , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/tratamiento farmacológico , Humanos , Vitamina K , Vitaminas/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA